# MRB 0.3% Serum Effectiveness on 2 Early Clinical Markers of Photoinduced Cutaneous Aging: Actinic Lentigo and Actinic Keratosis

> **NCT05152407** · NA · UNKNOWN · sponsor: **NAOS Institute of Life Science** · enrollment: 35 (estimated)

## Conditions studied

- Actinic Keratosis
- Actinic Lentigo

## Interventions

- **OTHER:** Topical application of MRB 0.3% serum and placebo serum (hemi face or skull)

## Key facts

- **NCT ID:** NCT05152407
- **Lead sponsor:** NAOS Institute of Life Science
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01
- **Primary completion:** 2023-07
- **Final completion:** 2023-07
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2021-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05152407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05152407, "MRB 0.3% Serum Effectiveness on 2 Early Clinical Markers of Photoinduced Cutaneous Aging: Actinic Lentigo and Actinic Keratosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05152407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*